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Purpose. Glial-derived neurotrophic factor (GDNF) is a potential therapy for stroke, Parkinson’s disease, or
drug addiction. However, GDNF does not cross the blood-brain barrier (BBB). GDNF is re-engineered as a
fusion protein with a chimeric monoclonal antibody (MAb) to the human insulin receptor (HIR), which acts
as a molecular Trojan horse to deliver the GDNF across the BBB. The pharmacokinetics (PK), toxicology,
and safety pharmacology of the HIRMAb-GDNF fusion protein were investigated in Rhesus monkeys.
Methods. The fusion protein was administered as an intravenous injection at doses up to 50 mg/kg over a
60 h period to 56 Rhesus monkeys. The plasma concentration of the HIRMAb-GDNF fusion protein was
measured with a 2-site sandwich ELISA.
Results. No adverse events were observed in a 2-week terminal toxicology study, and no neuropathologic
changes were observed. The PK analysis showed a linear relationship between plasma AUC and dose, a
large systemic volume of distribution, as well as high clearance rates of 8–10 mL/kg/min.
Conclusions. A no-observable-adverse-effect level is established in the Rhesus monkey for the acute
administration of the HIRMAb-GDNF fusion protein. The fusion protein targeting the insulin receptor
has a PK proﬁle similar to a classical small molecule.
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INTRODUCTION
Glial-derived neurotrophic factor (GDNF) is a potential
neurotherapeuticforbothacuteandchronicbraindisease(1–3).
The acute intra-cerebral injection of GDNF reduces the stroke
volume inexperimental ischemia(4).Theneurotrophinmustbe
administered to brain via a trans-cranial route, because GDNF
does not cross the blood-brain barrier (BBB) (5). The chronic
administration of GDNF could be therapeutic in both Parkin-
son’s disease (PD), as well as drug or alcohol addiction (6,7).
The trans-cranial injection of GDNF to humans with PD was
not therapeutic (8), because the GDNF did not reach the target
site (9), despite the direct pumping of the neurotrophin into the
human brain. The BBB is the limiting factor in the CNS drug
development of GDNF, or other recombinant proteins (10).
GDNF can be made transportable through the human
BBB by re-engineering the neurotrophin as a fusion protein
with a BBB molecular Trojan horse (4). The latter is an
endogenous peptide, or a peptidomimetic monoclonal anti-
body (MAb) against a receptor-mediated transcytosis system
within the BBB (11). The most potent molecular Trojan horse
is a MAb against the human insulin receptor (HIR) (12). Prior
work described the genetic engineering, transient expression,
and biochemical validation of a HIRMAb-GDNF fusion
protein (4). Following fusion of the amino terminus of the
mature human GDNF to the carboxyl terminus of the heavy
chain of the HIRMAb, the HIRMAb-GDNF retained high
afﬁnity binding for both the HIR, to mediate transport across
the BBB, and to the GDNF receptor (GFR)-α1, to mediate
pharmacologic action in brain behind the BBB (4). The
biological activity of the HIRMAb-GDNF was equivalent to
that of recombinant GDNF, and the stroke volume was
reduced 90% by the acute administration of the HIRMAb-
GDNF fusion protein in experimental ischemia (4).
The present studies were designed to support a phase I,
ﬁrst-in-human, dose-escalation clinical trial. These nonclinical
studies were performed in the Rhesus monkey to evaluate the
pharmacokinetics (PK), safety, tolerability, and tissue cross-
reactivity of this ﬁrst in class recombinant fusion protein. The
Rhesus monkey was chosen as the experimental model system,
because the HIRMAb cross reacts with the insulin receptor of
Old World primates, but not New World primates or rodents
(12). Moreover, there is no known MAb against the rodent
insulin receptor that could be used as a BBB molecular Trojan
horse. The route of administration, intravenous (IV) bolus
injection, used in these studies was chosen because this is the
intended route of administration in initial human trials.
MATERIALS AND METHODS
Production of CHO Line
A high producing eukaryotic host cell line was engi-
neered for manufacturing of the HIRMAb-GDNF fusion
1ArmaGen Technologies, Inc., 914 Colorado Ave., Santa Monica,
California 90401, USA.
2To whom correspondence should be addressed. (e-mail: wpardridge@
armagen.com)
Pharmaceutical Research, Vol. 26, No. 10, October 2009 (# 2009)
DOI: 10.1007/s11095-009-9939-6
2227 0724-8741/09/1000-2227/0 # 2009 The Author(s). This article is published with open access at Springerlink.comprotein. A tandem vector was engineered wherein the
expression cassettes for the heavy chain fusion gene, the light
chain gene, and the murine dihydrofolate reductase (DHFR)
gene were placed as tandem units on a single strand of DNA,
as described previously (13). DG44 Chinese hamster ovary
(CHO) cells, adapted to serum-free medium, were electro-
porated with the tandem vector, were selected with G418 and
hypoxanthine-thymine deﬁcient medium, and were ampliﬁed
with methotrexate treatment. The CHO line was subjected to
two rounds of dilutional cloning at one cell/well, and positive
clones were selected with measurement of medium human
IgG concentrations by enzyme-linked immunosorbent assay
(ELISA). The CHO line was stable through multiple
generations and produced medium IgG levels of 10–
20 mg/L in shake ﬂasks at a cell density of 1–2 million
cells/mL in serum-free medium (SFM). The DG44 CHO cell
line permanently transfected with the HIRMAb-GDNF gene
was made in-house and designated the CHO-HIRMAb-GDNF
line.
Manufacturing and Analysis
The HIRMAb-GDNF fusion protein was manufactured
in a setting that could be replicated in future Good
Manufacturing Practice (GMP) production for clinical trials.
A 50 L Wave bioreactor was seeded with the CHO-
HIRMAb-GDNF cells, and the medium was expanded to
23.5 L. The bioreactor was maintained for approximately
3 weeks in perfusion mode, where approximately 20 L of
SFM was perfused and collected each day. The cell density
reached 30 million cells/mL, and the medium IgG was
approximately 100 mg/L. Approximately 400 L of condi-
tioned medium was concentrated 10-fold with tangential ﬂow
ﬁltration, and the HIRMAb-GDNF fusion protein was
puriﬁed by sequential protein A afﬁnity chromatography,
cation exchange chromatography, anion exchange chroma-
tography, nano-ﬁltration, and ﬁnal diaﬁltration against 0.01 M
sodium acetate/0.14 M NaCl/pH=5.5 (ABS) buffer. The yield
of HIRMAb-GDNF fusion protein in the ﬁnal drug product
was 5 g of protein from the 23.5 L bioreactor. CHO host
protein was <1 parts per million (PPM), as determined by
ELISA (Cygnus Technologies, Southport, NC); protein Awas
<4 PPM, as determined by ELISA (Cygnus Technologies);
DNAwas <0.001 PPM as determined by real time PCR using
CHO cell DNA as the assay standard; endotoxin was <0.1
EU/mg protein, as determined by the limulus amebocyte
lysate assay (Lonza Biologics, Portsmouth, NH); and the
bioburden was <1 colony forming unit/mL (Bioreliance,
Rockville, MD). The ﬁnal product was a clear, colorless
solution of 6.5 mg/mL and conformed to speciﬁcations with
regard to identity (human IgG and GDNF Western blotting),
potency (HIR binding afﬁnity, GDNF receptor-α1 binding
afﬁnity), purity [sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE), size exclusion high perform-
ance liquid chromatography], and glycosylation analysis
(neutral monosaccharide, N-terminal oligosaccharide, Charles
River, Malvern, PA). Assays to assess GFRα1 binding and c-
ret kinase activation using a human neural cell line were
described previously (4). The protein was stable as a sterile
liquid stored at 4C for at least 1 year. The ﬁnal concentration
of the HIRMAb-GDNF fusion protein that was injected into
primates was conﬁrmed by UVabsorption spectrophotometry
(MPI Research, Mattawan, MI).
Housing of Animals
Rhesus monkeys (Macaca mulatta) of mixed sex were
used for all studies and were housed at MPI Research, Inc.
(Mattawan, MI) in stainless steel cages in a controlled
environment (18 to 28° C and 30-70% relative humidity) on
a 12-h light/dark cycle. Lab Diet Certiﬁed Primate Diet (PMI
Nutrition International) was provided twice daily. Tap water
was provided ad libitum. All aspects of the primate study
performed at MPI Research was conducted in strict compli-
ance with the United States Food and Drug Administration
(FDA) Good Laboratory Practice (GLP) Regulations, 21
CFR Part 58. All procedures were in compliance with the
Animal Welfare Act Regulations and were approved by the
Institutional Animal Care and Use Committee.
In vivo Study Design
Dose Selection
The animals were treated with either 0, 0.4, 2, or 10 mg/
kg of the HIRMAb-GDNF fusion protein administered as a
slow bolus intravenous injection over a 2-min period. In the
2-week toxicity study, the doses were administered every 12 h
for ﬁve consecutive doses over a 60-hr period, with a total
dosing of 0, 2, 10, and 50 mg/kg.
2-Week Toxicity Study
The initial clinical application of the HIRMAb-GDNF
fusion protein is projected to be as a single IV administration
within the ﬁrst 5 h of an acute ischemic stroke. Therefore, a
2-week toxicity study in the Rhesus monkey was designed.
For the repeat-dose, 2-week toxicity study, young adult,
experimentally naïve male and female Rhesus monkeys,
2.8–3.3 kg body weight, were assigned to one of four treat-
ment groups: (a) Group 1: 10 monkeys (5 male, 5 female)
were administered the ABS control article; (b) Group 2: 6
monkeys (3 male, 3 female) were administered a total of
2.0 mg/kg HIRMAb-GDNF fusion protein; (c) Group 3: 6
monkeys (3 male, 3 female) were administered a total of
10.0 mg/kg of HIRMAb-GDNF fusion protein; and (d)
Group 4: 10 monkeys (5 male, 5 female) were administered
a total of 50.0 mg/kg HIRMAb-GDNF fusion protein. In
groups 1 and 4, a total of 4 monkeys (2 males, 2 females) were
euthanized 1 day after the ﬁnal of ﬁve doses of the test or
control article. The remaining animals were euthanized on day
13 of the study period. A complete physical exam, and
opthalmoscopic exam, and electrocardiogram (ECG) were
conducted on all animals pre-test and prior to euthanasia.
Cageside observations were made twice per day, and a detailed
clinical exam was performed on each animal 1 hr post-dose.
Body weights were measured pre-test and twice a week during
the study. Food consumption was measured daily during the
study. Clinical pathologic examinations were performed pretest
and prior to euthanasia, and included urinalysis, coagulation
tests (prothombin, activated partial thromboplastin time), hem-
atologic proﬁle, chemistry panel (sodium, potassium, chloride,
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total protein, albumin, globulin, triglyceride, cholesterol,
glucose, aspartate aminotransferase, alanine aminotransferase,
gamma glutamyl transferase, and sorbitol dehydrogenase).
Organ weights were determined at necropsy for brain and
peripheral organs (adrenal, epididymis, heart, kidney, liver,
lung, ovary, pituitary, spleen, testis, thymus, and thyroid/
parathyroid). Hematoxylin and eosin microscopic analysis
was performed for these organs and 35 other peripheral
organs. Brain (cerebrum, midbrain, cerebellum, medulla/pons)
was evaluated by glial ﬁbrillary acid protein (GFAP) immu-
nocytochemistry, and by ﬂuoro Jade B ﬂuorescence micro-
scopy. The primate brain was sectioned and parafﬁn-blocked
into 9 blocks/brain, as described by Garman (14). The brain
was ﬁxed by head-only perfusion ﬁxation with 10% neutral
buffered formalin. Blood (1 mL) was removed from the
femoral vein and collected in tubes with K2-EDTA at 0, 2, 5,
3 0 ,6 0m i n ,2 ,4 ,2 3h r s ,a n da td a y1 3a f t e rt h eﬁrst IV
injection of the HIRMAb-GDNF fusion protein. Cerebrospi-
nal ﬂuid (CSF) was removed via the cisterna magna at 0, 3,
23, and 47 hrs after the ﬁrst IV injection of the HIRMAb-
GDNF fusion protein.
Single-Dose Safety Pharmacology Study
Young adult male Rhesus monkeys (body weight 3.4–
4.8 kg) were assigned to four treatment groups (6 monkeys/
group), and were administered 0, 0.4, 2.0, or 10.0 mg/kg of
HIRMAb-GDNF fusion protein by slow IV bolus injection
over 2 min on day 1. Animals were observed for changes in
cardiovascular, respiratory, and central nervous system (CNS)
function. The cardiovascular and pulmonary components of
the study were performed sequentially in 2 phases. Within
each phase, animals were treated and then given a 7-day
washout period before the next dose and phase. Both phases
and each treatment were conducted in the same four groups
of 6 monkeys per treatment group. All measurements were
made in conscious animals with surgically implanted tele-
metry transmitter devices. For the cardiovascular study, body
temperature, blood pressure (systolic, diastolic, mean), heart
rate, and ECG were monitored via telemetry for at least 2 h
before dosing and at least 20 h post-dosing. ECG parameters
included the QRS duration, the PR, RR, QT intervals, and
heart rate-corrected QT intervals. The data were collected in
1-minute frames and reported in 15-minute intervals. Cardiac
troponin levels were measured at the end of monitoring and
all values were <0.05 ng/mL. Arterial blood samples were
removed at 0, 0.5, 1, 2, and 4 hr post-dose for measurement of
pH, pCO2, pO2, bicarbonate, and CO-oximetry measure-
ments. For pulmonary testing, the animals were placed in
restraint chairs and ﬁtted with a helmet for monitoring
respiration. A continuous ﬂow of air was supplied and
removed from the helmet at a constant rate. A sampling line
was attached to the top of the helmet and connected to a
pressure transducer. Measured pulmonary parameters inclu-
ded the respiratory rate, tidal volume, and minute volume, and
were monitored for 30 min pre-dose and 3.5 h post-dose. The
data were collected in 1-minute frames and reported in
15-minute intervals. Detailed neurobehavioral functional
observational battery (FOB) measurements were made
coincident with the pulmonary testing at pretest, 4 hrs post-
dose, and 24 hrs post-dose. A modiﬁed FOB assessment was
made pre-dose and 75 min post-dose while the animal was
placed in the restraint chair, and included assessment of
mental status, lacrimation, salivation, gross motor move-
ments, cranial nerve function, and motor strength.
ELISA
Immunoreactive HIRMAb-GDNF Fusion Protein
The concentration of the HIRMAb-GDNF fusion pro-
tein in plasma and CSF was measured with a 2-site sandwich
ELISA, using the HIR ECD as the capture reagent, and an
anti-GDNF antibody as the detector reagent. The assay was
designed so that immunoreactivity would be measured only
on the intact HIRMAb-GDNF fusion protein, and requires
the presence of both parts of the fusion protein, the HIRMAb
moiety and the GDNF moiety, in order to measure a positive
signal. A murine MAb against the HIR (ab36550, Abcam,
Cambridge, MA) was plated in 96-well plates overnight at 4C
in 0.1 M NaHCO3/8.3 (100 ng/well); this antibody binds an
epitope on the HIR that is spatially removed from the
HIRMAb binding site. The solution was removed by
aspiration, the wells were washed with 0.01 M Tris/0.15 M
NaCl/7.4 (TBS), and 100 uL (200 ng)/well of lectin afﬁnity
puriﬁed HIR extracellular domain (ECD) was added fol-
lowed by a 90 min incubation at room temperature (RT). The
wells were washed with TBS/0.05% Tween-20 (TBST), and
either the sample or the HIRMAb-GDNF reference standard
was added in 100 uL/well followed by a 60 min incubation at
RT. A goat anti-human GDNF antibody (#AF-212-NA, R&D
Systems, Minneapolis, MN) was applied in a volume of
100 uL (400 ng)/well, followed by a 30 min incubation at
RT. Following washing with TBST, a conjugate of rabbit
anti-goat IgG and alkaline phosphatase (#AP-5000, Vector
Labs, Burlingame, CA) was applied in a volume of 100 uL
(500 ng)/well followed by a 45 min incubation at RT. The wells
were washed with TBST, and 100 uL/well of p-nitrophenyl-
phosphate (#P5994, Sigma Chemical Co., St. Louis, MO) was
incubated in the dark at RT for 15–30 min. The color
development was terminated by the addition of 100 uL/well
of 1.2 M NaOH, and color development was measured with
an ELISA plate reader at 405 nm. The limit of detection was
1 ng/well of HIRMAb-GDNF fusion protein. The standard
curve was determined with 0–300 ng/mL solutions of HIR-
MAb-GDNF fusion protein and was curvilinear, which was ﬁt
with a non-linear regression analysis using the WinNonlin
software (Pharsight, Mountain View, CA). The curve ﬁtting
yielded a correlation coefﬁcient (r
2) of >0.97. Accuracy was
conﬁrmed by spiking control Rhesus monkey plasma with 10–
100 ng/mL concentrations of the HIRMAb-GDNF fusion
protein. The intra-assay coefﬁcient of variation (CV) and the
inter-assayCVwere<15%.Assayspeciﬁcitywasdemonstrated
by showing that high concentrations (10,000 ng/mL) of either
the HIRMAb or human IgG1 caused no reaction in the
ELISA.
Anti-HIRMAb-GDNF Antibody Response
The presence of anti-HIRMAb-GDNF antibodies in
monkey plasma was detected with a 2-site sandwich ELISA,
2229 IgG-GDNF Fusion Proteinusing either the HIRMAb or the HIRMAb-GDNF fusion
protein as the capture reagent and biotinylated HIRMAb-
GDNF fusion protein as the detector reagent. As a positive
control, a rabbit anti-HIRMAb-GDNF antiserum was pre-
pared at Prosci, Inc. (Poway, CA). The rabbit anti-HIRMAb-
GDNF antisera and the respective preimmune rabbit sera
were diluted in 0.01 M NaHPO4/0.15 M NaCl/7.4 (PBS). The
chimeric HIRMAb, without the fused GDNF, or the HIR-
MAb-GDNF fusion protein was plated overnight at 4C in 96-
wells in 100 uL (250 ng)/well in 0.05 M NaHCO3/8.3. The
wells were blocked with PBS containing 1% bovine serum
albumin (PBSB), followed by the addition of 100 uL/well of a
1:50 dilution of Rhesus monkey plasma or various dilutions of
the rabbit anti-HIRMAb-GDNF antisera diluted in PBS.
After a 60 min incubation at 37C, the wells were washed with
PBSB, and the wells were incubated with biotinylated
HIRMAb-GDNF fusion protein (1.25 ug/mL) for 60 min.
The wells were washed with PBSB, followed by incubation
with 100 uL (500 ng)/well of a streptavidin-peroxidase
conjugate (#SA-5004, Vector Labs) for 30 min at RT. The
wells were washed with PBSB, and 100 uL/well of o-phenyl-
enediamine/H2O2 developing solution (#P5412, Sigma) was
added for a 20 min incubation in the dark at RT. The reaction
was stopped by the addition of 100 uL/well of 1 M HCl,
followed by the measurement of absorbance at 492 nm and
650 nm. The A650 was subtracted from the A492. The
(A492–A650) for the PBSB blank was then subtracted from
the (A492–A650) for the sample.
Pharmacokinetics Analysis
The rate of removal from plasma of the HIRMAb-GDNF
fusion protein was examined following acute administration to
Rhesus monkeys. The serum concentration of immunoreactive
HIRMAb-GDNF fusion protein (ng/mL) was divided by the
injection dose (ID) to compute the % ID/mL, and this data
was ﬁt to a 2-exponential equation: %ID/mL=A1e
−k1t+
A2e
−k2t; A1 and A2 are the intercepts, and k1 and k2 are the
slopes of each exponential function. These values were used to
compute the pharmacokinetics (PK) parameters, including the
mean residence time (MRT), the central volume of
distribution (Vc), the extra-vascular volume of distribution
(Vss), the area under the concentration curve (AUC), and the
systemic clearance (CL), as described previously (12). The
residual sum of squares ranged from 0.139 to 0.164, and
the standard deviation of each estimate ranged from 8–20% of
the respective mean for all estimated parameters. The non-
linear regression analysis was performed with the PAR
program of the BMDP2007 Statistical Software package
(Statistical Solutions, Dublin, Ireland).
Tissue-Cross Reactivity
Biotinylation of HIRMAb-GDNF
A biotinylated form of the HIRMAb-GDNF fusion
protein was produced for 2 applications: (i) a sandwich
ELISA measuring the formation of antibodies against the
fusion protein in primate plasma, and (ii) the tissue cross-
reactivity study. The HIRMAb-GDNF fusion protein (1.0 mL
of 6.6 mg/mL in ABS buffer) was biotinylated with 65 uL of
15 mg/mL sulfo biotin-LC-LC-N-hydroxysuccinimide, where
LC = long chain (#21338, Pierce Chemical Co., Rockford, IL)
by rocking 60 min at RT. The solution was transferred to an
Ultra-15 micro-concentrator (Millipore, Boston, MA) for
buffer exchange in ABS buffer and removal of the unreacted
biotin reagent. As a negative control, human IgG1/kappa
(#I5154, Sigma) was similarly biotinylated. The biotinylation
of the HIRMAb-GDNF fusion protein, or the human IgG1,
was conﬁrmed by SDS-PAGE and Western blotting, where
the blot was probed with a mixture of avidin and biotinylated
peroxidase. The control HIRMAb-GDNF fusion protein, or
the control human IgG1, gave no reaction in the Western
blot, whereas the biotinylated protein was strongly visualized
at the appropriate molecular size for both heavy chain and
light chain. The effect of biotinylation on the HIRMAb-
GDNF fusion protein binding to the HIR ECD was measured
by ELISA, as described previously (4). The biotinylated
HIRMAb-GDNF fusion protein bound with high afﬁnity to
the HIR ECD with an ED50 of 0.69±0.13 nM. The effect of
biotinylation on the HIRMAb-GDNF fusion protein binding
to the GFRα1 ECD was measured by ELISA, as described
previously (4). The biotinylated HIRMAb-GDNF fusion
protein bound with high afﬁnity to the GFRαl with an
ED50 of 2.4±0.7 nM.
Immunocytochemistry
A Tissue-cross reactivity (TCR) study of the HIRMAb-
GDNF fusion protein was performed with autopsy, archival
tissues from 3 healthy humans and 2 healthy Rhesus monkeys
using the avidin-biotin immunoperoxidase method under
GLP conditions by Charles River Laboratories Pathology
Associates (Frederick, MD). Fresh tissue was frozen in
cryomolds in Optimal Cutting Temperature (OCT) com-
pound, and frozen sections (5 micron) were prepared with a
cryostat. A total of 35 human and 34 Rhesus monkey organs
were examined as required by the FDA (15). The sections
were ﬁxed in acetone for 10 min and in 10% buffered
formalin for 10 sec just prior to staining. The primary
antibody was either the biotinylated HIRMAb-GDNF fusion
protein, or biotinylated human IgG1, used at a concentration
of 2 or 15 ug/mL. Following washing, the slides were exposed
to avidin and biotinylated peroxidase (ABC Elite, Vector
Labs, Burlingame, CA). No secondary antibody was required
since the primary antibody was biotinylated. The chromagen
was diaminobenzidine. Positive tissue staining was veriﬁed
with an anti-α2-microglobulin antibody. Speciﬁcity for the
HIR was examined with spot slides using recombinant HIR
(R&D Systems) and human parathyroid hormone-related
protein (PTHrP)-1-34 (Sigma Chemical Co.).
Statistical Analysis
Statistical signiﬁcance was determined at the p<0.05 level
using the analysis of variance (ANOVA) with Bonferroni
correction.
RESULTS
The 32 Rhesus monkeys in the multiple-dose, 2-week
terminal toxicity study were administered 0, 0.4, 2.0, or
2230 Pardridge and Boado10.0 mg/kg of the HIRMAb-GDNF fusion protein every 12 h
for 5 consecutive doses, or 0, 2, 10, or 50 mg/kg of the fusion
protein. Administration of the study drug was associated with
no deaths, no clinical ﬁndings, no change in food intake, no
change in body or organ weights, and no change in 40 clinical
pathology blood or urine tests (Methods). There was no
change in glycemic control in any of the four treatment
groups (Fig. 1). There were no macroscopic or microscopic
changes in peripheral organs, and no macroscopic or micro-
scopic changes in the brain (cerebrum, cerebellum, spinal
cord), based on hematoxylin & eosin staining, GFAP
immunocytochemistry, or ﬂuoro Jade B ﬂuorescence micro-
scopy. An additional 24 Rhesus monkeys were evaluated in a
single-dose safety pharmacology study, which showed no
changes in continuous ECG telemetry, pulmonary function
tests, arterial blood gases, or neurobehavioral functional
observational battery. No increases in cardiac troponin I in
plasma were detected.
A 2-site sandwich ELISA was developed for the
measurement of immunoreactive HIRMAb-GDNF fusion
protein in plasma and CSF. The structure of the assay is
shown in Fig. 2A, which shows that the HIR ECD is used as
the capture reagent, and an anti-GDNF antibody is used as
the detector reagent. Therefore, the assay only measures
intact HIRMAb-GDNF fusion protein, and does not detect
the HIRMAb without the attached GDNF (Methods). The
spiking of control Rhesus monkey plasma with known
concentrations of the HIRMAb-GDNF reference standard
yielded a linear increase in the concentration of fusion
protein detected by the assay (Fig. 2B). The time-dependent
changes in plasma concentration of the HIRMAb-GDNF
fusion protein is shown in Table I following the IV injection of
0.4, 2, or 10 mg/kg of the fusion protein. The plasma concen-
tration curves shown in Table I were ﬁt to a 2-exponential PK
model (Methods) to yield the PK parameters in Table II.T h e
PK proﬁle was linear, as there was a linear relationship between
plasma AUC and dose of HIRMAb-GDNF fusion protein
(Fig. 3).The fusion protein was rapidlycleared by tissues invivo
as the systemic clearance was 8–10 mL/kg/min (Table II). The
extravascular volume of distribution, Vss, was large, 3000–
6000 mL/kg, and was more than 10-fold greater than the central
volume of distribution, Vc (Table II). The CSF level was below
the limit of detection except in the high dose group. The CSF
concentration of the HIRMAb-GDNF fusion protein was 1.2±
0.6, 3.0±1.1, and 3.6±0.9 ng/mL (mean ± SE, n=10) at 3, 23, and
47 h after injection, respectively. There was no change in the
total protein content of the CSF in any group at any time
relative to the control group.
A 2-site sandwich ELISA was developed to measure the
formation of antibodies against the HIRMAb-GDNF fusion
protein, and the structure of the ELISA is outlined in Fig. 4A.
Owing to the bivalency of antibody binding, the anti-fusion
protein antibody binds both the HIRMAb-GDNF capture
reagent and the biotinylated HIRMAb-GDNF detector
reagent (Fig. 4A). As a positive control, a rabbit anti-
HIRMAb-GDNF antiserum and a respective pre-immune
serum were tested for reactivity at dilutions ranging from 1:30
to 1:100,000. The pre-immune serum gives no reaction in the
assay, whereas the rabbit antiserum is strongly reactive
(Fig. 4B). The antiserum reactivity in the ELISA was
somewhat higher when the HIRMAb was used as the
capture reagent, as opposed to the HIRMAb-GDNF fusion
protein (Fig. 4B). Reaction above the pre-immune level is
observed at 1:100,000 dilutions, and the dilution that gives
50% of the maximal titer is approximately 1:2,000 (Fig. 4B).
The immune signals for a 1:50 dilution of terminal primate
plasma are shown in Fig. 4C for 24 Rhesus monkeys. Only
monkeys in the highest 2 dose groups show any immune
response at 13 days following ﬁve consecutive doses of the
HIRMAb-GDNF fusion protein over a 60-h period at days
1–3, and only 25% of these monkeys showed an immune
response producing an ELISA signal above a cutoff of 0.3
(Fig. 4C).
Biotinylated HIRMAb-GDNF gave strong staining on
spot slides of human insulin receptor, but did not react with
spot slides of human PTHrP. The biotinylated hIgG1 did not
react with either protein on spot slides. Biotinylated human
IgG1 did not react with any human or Rhesus monkey
tissue sections at 2 or 15 ug/mL, although all tissues stained
with an antibody to human β2-microglobulin. The tissue
Fig. 1. Plasma glucose in 4 treatment groups of Rhesus monkeys at
the pre-test, and various times after the bolus IVinjection of 0–10 mg/
kg of the HIRMAb-GDNF fusion protein. Data are mean ± S.D. (n=
6–10 animals per group). There are no signiﬁcant changes in plasma
glucose among the treatment groups.
Fig. 2. (A) Structure of the 2-site ELISA used to measure the
concentration of the HIRMAb-GDNF fusion protein. A mouse
monoclonal antibody (mMAb) against the HIR is plated, which
captures the HIR ECD derived from CHO cells. The HIRMAb part
of the fusion protein binds the HIR ECD, and the GDNF part of the
fusion protein is bound by a goat anti-GDNF antibody, which is
bound by a conjugate of a rabbit anti-goat (RAG) antibody and
alkaline phosphatase (AP). (B) Control Rhesus monkey plasma was
spiked with 5 different doses of the HIRMAb-GDNF reference
standard. There is a linear correlation between the observed
concentration and the predicted concentration of fusion protein.
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at 15 ug/mL, as compared to 2 ug/mL. There was low level
staining in virtually all human or primate tissues. The
human or primate tissues that yielded frequent, strong
staining at 15 ug/mL are listed in Table III. In the CNS,
neurons, glial cells, and endothelium were strongly positive
in human tissues. Endothelial staining was strong in the
cerebrum, cerebellum, spinal cord, and eye in humans.
Epithelial cells and mesothelial cells in diverse tissue in
humans and primates yielded strong immunocytochemical
staining (Table III). Tissue macrophages also were strongly
stained by the biotinylated HIRMAb-GDNF fusion protein
at 15 ug/mL. The HIRMAb-GDNF also bound to the
endothelium of brain and eye in the primate, but these
tissues are not listed in Table III, because the staining was
designated as moderate, not strong. Similarly, the HIRMAb-
GDNF strongly stained neurons and glial cells in brain and
spinal cord of humans (Table III) and gave moderate
staining of these cells in primates. The HIRMAb-GDNF
fusion protein bound to epithelial and mesothelial cells in
different tissues in both humans and primates (Table III).
DISCUSSION
This study demonstrates that single intravenous injec-
tions of the HIRMAb-GDNF fusion protein have no adverse
effects in 56 Rhesus monkeys subjected to either a 2-week
terminal toxicity study or an acute safety study. The plasma
pharmacokinetic (PK) proﬁle and tissue cross-reactivity
proﬁle are reported. The study establishes the no-observable-
adverse-effect level (NOAEL) for acute intravenous admin-
istration of the HIRMAb-GDNF fusion protein in future
human clinical trials. This study is the ﬁrst such evaluation of
a molecular Trojan horse recombinant fusion protein, wherein
the Trojan horse is a receptor-speciﬁc MAb against an
endogenous BBB receptor, the HIR.
GDNF could be developed as a neurotherapeutic for
humans both as an acute, single dose treatment for stroke (4)
or as a chronic treatment for conditions such as PD (2) or drug
addiction (6,7). Since GDNF does not cross the BBB, this
neurotrophin was administered to patients with PD by direct
intra-cerebral injection. Following initial open label clinical
trials with intra-cerebral GDNF (16,17), a controlled clinical
trial with this delivery system did not show clinical beneﬁt( 8).
However, the design of this clinical trial has been questioned
(18). An alternative approach to the delivery of GDNF to brain
is the use of IgG-GDNF fusion proteins, wherein the IgG part
acts as a molecular Trojan horse to deliver the GDNF to brain
via the trans-vascular route. In this respect, the trans-vascular
delivery of GDNF is analogous to the brain delivery of L-
DOPA for the treatment of PD. The subsequent action of L-
DOPA or GDNF in brain is a function of the regional
expression of thetarget receptor.Although theGDNFreceptor,
GFRα1, is up-regulated in brain injury (19)o rs t r o k e( 20), the
co-expression of GFRα1 and the c-ret kinase in control brain is
highly circumscribed (21,22). An advantage of a trans-vascular
delivery of GDNF to brain is that an invasive, neurosurgical
procedure is not required.
The trans-vascular delivery of GDNF to brain is possible
following the re-engineering of this neurotrophin as a
HIRMAb-GDNF fusion protein. This fusion protein tra-
verses the BBB via receptor-mediated transcytosis (RMT)
on the BBB insulin receptor. The BBB HIR normally serves
to mediate the RMT of endogenous insulin (23,24). The
HIRMAb binds an exofacial epitope on the HIR, and this
binding enables the transport of the antibody across the BBB
and into brain (12). The binding of the HIRMAb to the
human BBB and the in vivo BBB transport of the HIRMAb
in the Rhesus monkey have been demonstrated previously for
Table I. HIRMAb-GDNF Fusion Protein Plasma Concentrations in
Rhesus Monkeys
ng/mL
minutes 0.4 mg/kg 2.0 mg/kg 10.0 mg/kg
2 1,356±128 7,625±598 39,139±7,524
5 772±139 4,005±503 10,787±1,174
30 121±21 532±70 1,246±147
60 100±18 395±38 1,048±78
120 52±9 212±28 661±100
240 46±10 188±22 635±104
1380 3.7±2.5 35±6 156±44
Mean ± SE (n=6–10).
Table II. Pharmacokinetic Parameters
HIRMAb-GDNF dose
Parameter units 0.4 mg/kg 2.0 mg/kg 10.0 mg/kg
A1 %ID/mL 0.113±0.022 0.123±0.026 0.311±0.132
k1 min
−1 0.114±0.022 0.114±0.021 0.449±0.112
A2 %ID/mL 0.00645±0.00095 0.00477±0.00076 0.00315±0.00040
k2 min
−1 0.00228±0.00021 0.00154±0.00022 0.00133±0.00021
MRT min 327±32 484±77 583±104
Vc mL/kg 271±54 256±53 107±43
Vss mL/kg 2767±321 3789±561 6372±993
AUCss %ID•min/mL 3.83±0.32 4.19±0.41 3.06±0.34
AUCss ug•min/mL 47.4±4.0 255±25 916±101
CL mL/kg/min 8.45±0.72 7.84±0.78 10.94±1.24
BW kg 3.10±0.32 3.05±0.20 2.99±0.18
Dose μg 1238±126 6090±391 29930±1802
No. animals 6 6 10
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(12,25,26). In contrast, there is no BBB receptor for a
neurotrophin such as GDNF, and GDNF does not cross the
BBB (5). Similar to the HIRMAb, the HIRMAb-GDNF
fusion protein also crosses the BBB in the adult primate, and
the brain uptake is 0.55±0.04 % of injected dose (ID) per
brain (unpublished observations). Given a primate body
weight of 5 kg and a fusion protein injection dose of
0.2 mg/kg, the brain concentration of the HIRMAb-GDNF
fusion protein increases to 55 ng/gram. Since the fusion
protein is approximately 20% GDNF (4), the brain concen-
tration of exogenous GDNF is increased to 11 ng/gram with a
0.2 mg/kg dose of fusion protein. The endogenous GDNF
concentration in human brain is 0.68 ng/gram in the putamen
(27). Therefore, an injection dose of HIRMAb-GDNF fusion
protein of only 0.2 mg/kg causes an approximately 15-fold
increase in putamen GDNF. Elevations in striatal GDNF of
this magnitude are neuroprotective in experimental PD (28).
The potential toxicity of administration of large doses of
the HIRMAb-GDNF fusion protein was examined in the
present study, and the fusion protein was found to have a
remarkable safety proﬁle (Results). High doses of a mono-
clonal antibody against the insulin receptor could have either
agonist or antagonist properties at the insulin receptor. In this
event, administration of the HIRMAb, or an HIRMAb fusion
protein that retains high afﬁnity for the HIR, could cause
either hypo-glycemia or hyper-glycemia. However, the
present study shows no change in the plasma glucose, even
in the high dose treatment group (Fig. 1). Plasma concen-
trations of the HIRMAb-GDNF fusion protein as high as 39
ug/mL (Table II), which is >200 nM, have no effect on glycemic
control (Fig. 1). The absence of an effect on circulating glucose
isattributedtothe fact thatthe bulkofinsulin-responsive tissues
in skeletal muscle and fat are perfused by continuous endothe-
lium, which does not express an insulin receptor (29). Insulin,
which is only 5 kDa, crosses the endothelium in peripheral
tissues passively through pores (30). The passive diffusion
across peripheral endothelial barriers of the 190 kDa HIR-
MAb-GDNF fusion protein is more restrictive. In contrast, the
expression of the insulin receptor on the BBB enables ligands,
such as insulin or the HIRMAb, to rapidly enter brain within
minutes of intravenous administration (12,24).
The present study was designed to support future clinical
trials of the acute administration of the HIRMAb-GDNF
fusion protein to humans. GDNF is a potent neuroprotective
agent in cerebral ischemia, as topical administration of GDNF
to ischemic brain reduces the size of the cerebral infarct
Fig. 3. Linear relationship between the plasma AUC and the dose of
HIRMAb-GDNF fusion protein. Data are mean ± S.D. (n=6–10
animals/group).
Fig. 4. (A) Structure of the 2-site ELISA for detection of antibodies against the HIRMAb-GDNF fusion protein. The
HIRMAb or the HIRMAb-GDNF fusion protein is used as the capture reagent, and the biotinylated HIRMAb-GDNF
fusion protein is used as the detector reagent, along with a complex of streptavidin (SA) and horseradish peroxidase (HRP);
the biotin moiety is designated, ‘B’.( B) Absorbance at various dilutions of a rabbit antiserum prepared against the
HIRMAb-GDNF fusion protein, and the respective pre-immune serum (triangles). Either the HIRMAb (squares) or the
HIRMAb-GDNF fusion protein (diamonds) was used as the capture reagent. Data are means of duplicates that varied
<10%. (C) Absorbance at 1:50 dilutions of Rhesus monkey plasma taken at day 13, following the administration of 0, 0.4, 2,
or 10 mg/kg of the HIRMAb-GDNF fusion protein every 12 h for 5 consecutive doses over days 1–3 of the study. The total
dose of fusion protein given over the 60-hr period was 0, 2, 10, and 50 mg/kg (Methods). A signiﬁcant immune reaction is
registered with an (A490–A655) signal >0.3.
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imental stroke, because (a) GDNF does not cross the BBB,
and (b) the BBB is intact for at least 6 h following stroke (32),
during which neuroprotection is still possible. Although the
BBB does become permeable in stroke (33), this disruption
occurs 12–24 h after stroke, when it is no longer possible to
rescue ischemic neurons. The intra-cerebral injection of the
HIRMAb-GDNF fusion protein in a rat middle cerebral
artery occlusion (MCAO) model caused a 90% reduction in
stroke volume (4). The HIRMAb-GDNF fusion protein was
administered in the rat MCAO model via a trans-cranial
route, because the HIRMAb does not react with the rodent
insulin receptor. No surrogate antibody could be used, since
there is no known MAb against the rodent insulin receptor
that could be used as a BBB molecular Trojan horse.
The HIRMAb does cross-react with the insulin receptor
of Old World primates, such as the Rhesus monkey, but not
the more distant New World primate, such as the squirrel
monkey (12). Immunocytochemistry of Rhesus monkey brain
using the HIRMAb as the primary antibody shows high
binding of the HIRMAb to the BBB insulin receptor, which
parallels other studies showing high binding of insulin (23), or
the HIRMAb (12), to capillaries isolated from human
autopsy brain. The high binding of the HIRMAb to the
human and Rhesus monkey insulin receptor is further
corroborated by the tissue cross-reactivity (TCR) immunocy-
tochemistry reported in the present study (Table III). The
TCR study employed a biotinylated form of the HIRMAb-
GDNF fusion protein so as to avoid non-speciﬁc immune
reactions caused by binding of an anti-human IgG secondary
antibody to the endogenous IgG in human or primate tissues.
The HIRMAb-GDNF fusion protein retained high afﬁnity
binding for both the HIR and the GFRα1 following
biotinylation (Methods). The endothelium of brain and spinal
cord gave strong immune staining with the HIRMAb-GDNF
in human tissues (Table III).
The Rhesus monkey was used to assess the safety and
potential toxicity of the HIRMAb-GDNF fusion protein
owing to the limited species cross-reactivity of the HIRMAb.
The present study shows no adverse events are caused by the
serial administration of ﬁve doses of the HIRMAb-GDNF
fusion protein over the range of 0.4–10 mg/kg for a single
injection, or 2–50 mg/kg over a 60-hr period (Results).
Following the repeated administration of ﬁve consecutive
doses over a 60 hr period of the HIRMAb-GDNF fusion
protein, a measureable immune response, deﬁned as a
(A490–A655) signal above a cutoff of 0.3, was observed in
25% of the animals in the highest two dosage groups
(Fig. 4C). This immune response, at 1:50 dilutions of primate
plasma, was minimal compared to that of high dilutions of a
rabbit antiserum prepared against the HIRMAb-GDNF
fusion protein (Fig. 4B). The immune signal for either the
rabbit antiserum, or the primate plasma samples, was
measured with either the HIRMAb or the HIRMAb-GDNF
fusion protein as the capture reagent. A comparable immune
signal was observed for either the rabbit antiserum or the
primate plasma samples, although the immune signal was
slightly higher when the HIRMAb was plated as the capture
reagent, as compared to the HIRMAb-GDNF fusion protein,
for the rabbit antiserum (Fig. 4B), or the primate plasma
samples. These observations suggest there is not a signiﬁcant
immune response to the GDNF part of the HIRMAb-GDNF
fusion protein. Immune tolerance to IgG fusion proteins is
induced by amino acid sequences within the constant region
of the IgG moiety called Tregitopes (34).
The analysis of the plasma PK proﬁle of the HIRMAb-
GDNF fusion protein was enabled by the development of a
speciﬁc 2-site ELISA outlined in Fig. 2A. The HIR ECD is
used as the capture reagent, and an anti-GDNF antibody is
used as the detection reagent. Only intact HIRMAb-GDNF
fusion protein is detected by the assay, as the HIRMAb alone
is not reactive in the assay (Methods). The plasma concen-
trations of the HIRMAb-GDNF (Table I) were analyzed with
a 2-compartmental model (Methods) to yield the PK param-
eters in Table II. The PK analysis shows that the rate of
clearance of the HIRMAb-GDNF fusion protein from the
central compartment is rapid, similar to that of a small
molecule, and different from the clearance of a classical
MAb-therapeutic. The extravascular volume of distribution,
Vss, of a monoclonal antibody is generally similar to the
central volume of distribution, Vc, owing to limited egress of
the MAb from plasma to the extra-vascular space. However,
in the case of the HIRMAb-GDNF fusion protein, the Vss is
3,000 to 6,000 mL/kg and is 10-fold to 60-fold greater than the
Vc (Table II). The systemic clearance rate, CL, is 8–10 mL/kg/
min (Table II), which is comparable to the systemic clearance,
Table III. Human and Rhesus Monkey Tissue Cross-Reactivity of
HIRMAb-GDNF Fusion Protein
Human Rhesus monkey
Number of tissues
examined
35 34
Number of donors
Examined
32
Strongly reactive on
Neurons and glial cells
cerebrum
cerebellum
spinal cord
Epithelial cells eye adrenal gland
placenta placenta
breast breast
ovary ovary
prostate prostate
testis testis
thyroid gland thyroid gland
ureter ureter
uterus pancreas
skin
urinary bladder
Endothelial cells cerebrum
cerebellum
spinal cord
eye
Mesothelial cells spleen spleen
Oviduct small intestine
testis liver
urinary bladder
uterus
Hematopoietic cells bone marrow bone marrow
Smooth muscle cells cerebrum
eye
The above tissues exhibited strong, frequent staining at the high
concentration (15 ug/mL) of biotinylated HIRMAb-GDNF.
2234 Pardridge and Boado27 mL/kg/min, of a small molecule in the Rhesus monkey
(35). The systemic clearance of the HIRMAb-GDNF fusion
protein is higher than previous estimates for the systemic
clearance of the HIRMAb-neurotrophin fusion protein,
which is about 1.0 mL/kg/min in a 5-year old adult Rhesus
monkey (13). In the present study, the PK analysis was
performed on Rhesus monkeys of 2.8–3.3 kg body weight
(Methods), which are pre-pubescent animals (36). Younger
animals express higher levels of insulin receptor, transport
circulating insulin, and possibly the HIRMAb at faster
rates (37).
In conclusion, these studies show there are no adverse
events associated with the acute administration of large doses
of the HIRMAb-GDNF fusion protein, and establish a
NOAEL for future human clinical trials. If further drug
development of the HIRMAb-GDNF fusion protein is
successful, it would be possible to re-engineer other protein
pharmaceuticals for targeted drug delivery across the human
BBB with the molecular Trojan horse technology
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